JCR Pharmaceuticals Showcases Promising Gene Therapy Data at ASGCT Meeting
JCR Pharmaceuticals presented preclinical data on its novel gene therapy platform, JUST-AAV, at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting. The platform is designed to enhance targeted delivery to the central nervous system (CNS) and reduce liver tropism, improving the safety and efficacy of AAV-based gene therapies. The data demonstrated efficient delivery of therapeutic agents to the CNS, offering potential new treatment options for challenging CNS diseases. The research highlights the platform's promise in advancing gene therapy for neurodegenerative disorders and other complex healthcare challenges. 
